COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study of ABT-414 in Subjects With Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01741727
Recruitment Status : Completed
First Posted : December 5, 2012
Last Update Posted : November 20, 2017
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) )

Brief Summary:
A study of ABT-414 in subjects with solid tumors.

Condition or disease Intervention/treatment Phase
Squamous Cell Tumors Drug: ABT-414 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 57 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2 Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-414 in Subjects With Advanced Solid Tumors Likely to Over-Express the Epidermal Growth Factor Receptor (EGFR)
Study Start Date : October 2012
Actual Primary Completion Date : November 2015
Actual Study Completion Date : November 2015

Arm Intervention/treatment
Experimental: ABT-414
Subjects with solid tumors (Phase 1) and squamous non-small cell lung cancer (NSCLC) (Phase 2)
Drug: ABT-414
ABT-414 will be administered by intravenous infusion.

Primary Outcome Measures :
  1. Phase 1 - Safety (Number of subjects with adverse events and/or dose limiting toxicities) [ Time Frame: Every 1-3 weeks for an average of 20 weeks ]
    Evaluation of vital signs, clinical lab testing, adverse event monitoring, physical exam and electrocardiogram (ECG) (periodic) under different dosing schedules, drug infusion times, and manufacturing processes.

  2. Phase 1 - Pharmacokinetic profile [ Time Frame: Multiple timepoints Week 1 and Week 7 ]
    Cmax, Cmin, and half-life

  3. Phase 2 - Efficacy [ Time Frame: Every 6-9 weeks for an average of 20 weeks ]
    Objective response per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST)

Secondary Outcome Measures :
  1. Phase 2- Safety (Scheduled study visits occurring on average every 3 weeks) [ Time Frame: Followed on average every 3 weeks for approximately 20 weeks ]
    Evaluation of vital signs, clinical lab testing, and adverse event monitoring, physical exam, and electrocardiogram (periodic)

  2. Phase 2- Pharmacokinetic profile [ Time Frame: Multiple timepoints Week 1 ]
    Cmax, Cmin, and half-life

  3. Phase 1&2 - QT assessment [ Time Frame: Week 1 ]
    Triplicate electrocardiograms

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subjects must have a solid tumor type likely to over-express Epidermal Growth Factor Receptor (EGFR) (Phase 1)
  2. Subjects have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2
  3. Subjects have available tumor tissue
  4. Subjects have adequate bone marrow, renal, and hepatic function as follows: Bone marrow: Absolute neutrophil count (ANC) >/= 1,500/mm3 Platelets >/= 100,000/mm3; Hemoglobin >/= 9.0 g/dL Renal function: Serum creatinine </= 1.5 times the upper limit of the institution's normal range Hepatic function: Bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) </= 1.5 times the upper limit of the institution's normal range. Subjects with liver metastasis may have an AST and ALT of </= 5.0 x the upper limit of normal.
  5. Subjects in the Phase 2 portion must have squamous cell Non-Small Cell Lung Cancer (NSCLC)
  6. Eligibility is restricted to subjects with confirmed EGFR amplification in the EGFR amplified cohort

Exclusion Criteria:

  1. The subject has uncontrolled metastases to the central nervous system (CNS). Subjects with brain metastases are eligible provided they have shown clinical and radiographic stable disease for at least 28 days after definitive therapy and have not received prior whole brain radiation (Phase 1 only).
  2. The subject has received anticancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal, biologic, or any investigational therapy within a period of 28 days prior to the first dose of ABT-414.
  3. The subject has unresolved clinically significant toxicities from prior anticancer therapy, defined as any Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 or higher.
  4. The subject had had major surgery within 28 days prior to the first dose of ABT-414.
  5. The subject has a history of immunologic reaction to any Immunoglobulin G (IgG) containing agent.
  6. Phase 2 portion only: The subject has previous or concurrent cancer that is distinct in primary site or histology from NSCLC, except cervical carcinoma in situ, non-melanoma carcinoma of the skin or in situ carcinoma of the bladder. Any cancer curatively treated greater than 3 years prior to entry is permitted.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01741727

Layout table for location information
United States, Arizona
Site Reference ID/Investigator# 90333
Scottsdale, Arizona, United States, 85258
United States, Illinois
Site Reference ID/Investigator# 83156
Chicago, Illinois, United States, 60637
United States, Massachusetts
Site Reference ID/Investigator# 117516
Boston, Massachusetts, United States, 02215
Site Reference ID/Investigator# 83154
Boston, Massachusetts, United States, 02215
United States, Texas
Site Reference ID/Investigator# 83155
San Antonio, Texas, United States, 78229
Site Reference ID/Investigator# 89035
Ottawa, Canada, K1H 8L6
Sponsors and Collaborators
AbbVie (prior sponsor, Abbott)
Layout table for investigator information
Study Director: Christopher Ocampo, MD AbbVie
Publications of Results:
Layout table for additonal information
Responsible Party: AbbVie (prior sponsor, Abbott) Identifier: NCT01741727    
Other Study ID Numbers: M13-379
First Posted: December 5, 2012    Key Record Dates
Last Update Posted: November 20, 2017
Last Verified: February 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Squamous Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type